### JCO2 Rec'd PCT/PTO 12 MAY 2005

HO4) POT-

Under the Paperwork Red

Signature

Typed or printed name

U.S. Patent and Trademark U.S. Patent and Trademark ct of 1995, no persons are required to respond to a collection of information

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark
Figure 1.S. DEPARTMENT OF COMMERCE pond to a collection of information in displays a valid OMB control number.

	-	Application Number	or	10/528,640		
TRANSMITTAL	-	Filing Date	Ci			
FORM		First Named Inver		Deroger 2, 2003  Becker		
MAY 1 2 2005			itor			
		Art Unit		Not Yet Assigned		
Yto be used for all correspondence after		Examiner Name		Not Yet Assigned		
otal NumbeA6 ages in This Submiss	ion	Attorney Docket N	lumber	ASZN0019-100 (100848-1P US)		
	ENCLO	SURES (check all the	at apply)			
Fee Transmittal Form	Drawing(s	)		After Allowance Communication to TC		
Fee Attached	Licensing	-related Papers		Appeal Communication to Board of Appeals and Interferences		
Amendment / Reply	Petition			Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)		
After Final	Provision	Convert to a Application		Proprietary Information		
Affidavits/declaration(s)		Attorney, Revocation f Correspondence Add	dress	Status Letter		
Extension of Time Request	Terminal I	Disclaimer		Other Enclosure(s) (please identify below):		
¬	Request f	or Refund		- Table A		
Express Abandonment Request	CD, Numb	per of CD(s)		<ul><li>Statement Under 37 CFR 3.73(b)</li><li>executed Assignment</li></ul>		
Information Disclosure Statement	☐ Lan	dscape Table on CD		- Return Postcard		
Certified Copy of Priority Document(s)	Remarks					
Reply to Missing Parts/ Incomplete Application						
Reply to Missing Parts under 37 CFR1.52 or 1.53						
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
Firm Cozen O'Connor, P.C.						
Signature	Parke					
Printed Name	Paul K. Legaard					
Date	lomo	4 2005	Reg. No.	38,534		
	CERTIFICA	TE OF TRANSMISS	SION/MAII	ING		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

(0 MAY 205

Paul K. Legaard

# TABLE A

				ALIPPATATION TO THE REAL PROPERTY OF THE PROPE
Our Ref.	Serial No.	First Inventor	Examiner	Title
AstraZeneca Ref.	Filing Date		Art Unit	
ASZN0005-100 100368-1P US	10/477,851 5/16/02	Brown	Rita J. Desai 1625	4-(phenyl-piperidin-4-ylidene-methyl)-benzamide Derivatives And Their Use For The Treatment Of Pain, Anxiety Or Gastrointestinal Disorders
ASZN0005-101 100369-1P US	10/477,854 5/16/02	Brown	Celia C. Chang 1625	4-(phenyl-piperdin-4-ylidene-methyl)-benzamide Derivative And Their Use For The Treatment Of Pain, Anxiety Or Gastrointestinal Disorders
ASZN0005-102 100372-1P US	10/477,853 5/16/02	Brown	Rita J. Desai 1625	4-(Phenyl-(piperidin-4-yl)-amino)-benzamide Derivatives And Their Use For The Treatment Of Pain, Anxiety Or Gastrointestinal Disorders
ASZN0005-103 100373-1P US	10/477,633 5/16/02	Brown	Rita J. Desai 1625	4-(phenyl-(piperidin-4yl)-amino)-benzamide Derivatives And Their Use For The Treatment Of Pain, Anxiety Or Gastrointestinal Disorders
ASZN0005-104 100375-1P US	10/477,636 5/16/02	Brown	· Rita J. Desai 1625	4-(phenyl-(piperidin-4yl)-amino)-benzamide Derivatives And Their Use For The Treatment Of Pain, Anxiety Or Gastrointestinal Disorders
ASZN0006-100 100514-1P US	10/497,565 12/11/02	Leung	Not Yet Assigned	Benzodiazepine Derivatives, Preparation Thereof And Use Thereof
ASZN0007-100 100590-1P US	10/498,864 12/17/02	Cheng	Not Yet Assigned	Therapeutic Heterocycles
ASZN0008-100 100100-1P US	10/333,669 1/21/03	Patel	Raymond K. Covington 1625	Process For Asymmetric Synthesis Of Substituted 1,4- Dihydropyridines
ASZN0009-100 100102-1P US	10/333,654 9/5/03	Patel	Alton N. Pryor 1616	Process For Synthesis Of Alpha, Beta-unsaturated Ketones

--

<u>٠</u> -	•					r	Rec'	d PCT	/PTO	12 M	AY 2005
Method For The Treatment Of Overactive Bladder	Compounds And Method For The Treatment Of Overactive Bladder	Method	N-type Calcium Channel Antagonists For The Treatment Of Pain	N-type Calcium Channel Antagonists For The Treatment Of Pain	N-type Calcium Channel Antagonists For The Treatment Of Pain	Cd45 Inhibitors	Cd45 Inhibitors	N-( 2-phenyl-3-aminopropyl)naphtamides	Cyclized Benzamide Neurokinin Antagonists For Use Therapy	Spunodwoo	
Raymond J. Henley III 1614	Not Yet Assigned	D. Margaret M. Seaman 1625	Not Yet Assigned 1614	D. Margaret M. Seaman 1625	Not Yet Assigned	Maury A. Audet 1654	Kevin Weddington 1614	Shailendra Kumar 1621	Bruck Kifle 1624	Celia C. Chang 1625	2
Bialecki	Bialecki	Jones	Chapdelaine	D'Amico	D'Amico	Chapdelaine	Chapdelaine	Bernstein	Bernstein	Shenvi	
10/494,387 4/30/04	10/494,195 11/1/02	10/502,191	10/415,853 11/3/03	10/488,066 8/9/04	10/488,025 8/23/02	10/168,758 11/25/02	10/168,477 11/25/02	10/333,658 7/31/01	10/381,755 3/26/03	10/450,284 12/20/01	·
ASZN0010-100 · 100541-1P US	ASZN0010-101 100542-1P US	ASZN0011-100 100570-1P US	ASZN0012-100 100186-1P US	ASZN0012-101 100463-1P US	ASZN0012-102 100464-1P US	ASZN0013-100 Z70624-1P US	ASZN0013-101 Z70626-1P US	ASZN0014-100 100121-1P US	ASZN0015-100 100174-1P US	ASZN0016-100 100237-1P US	

	•			
ASZN0017-100 Z70402-1P US	09/806,657 10/4/99	Bernstein	Not Yet Assigned	Naphthalenecarboxamides As Tachykinin Receptor Antagonists
ASZN0018-100 100003-2P US	11/042,752 1/24/05	Albert	Not Yet Assigned	Neurokinin Antagonists For Use As Medicaments
ASZN0019-100 100848-1P US	10/528,640 10/2/03	Becker	Not Yet Assigned	Novel Lactams And Uses Thereof



TED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

#### STATEMENT UNDER 37 CFR 3.73(b)

Applicant, AstraZeneca AB, a corporation, states that it is:

the assignee of the entire right, title, and interest of the applications identified in Table A attached hereto.

The extent (by, percentage) of its ownership interest is 100% in the patent applications identified in Table A by virtue of:

a copy of the pertinent assignment from the inventor(s) of the patent applications identified in Table A is enclosed herewith.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Respectfully submitted,

**ASTRAZENECA AB** 

Date: \_\_13 April 2005%

Name: Christer Wahlström

Title: Director Patent Operations



#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Date: 13 April 2005

Sir:

## POWER OF ATTORNEY WITH REVOCATION AND CHANGE OF CORRESPONDENCE ADDRESS

I hereby revoke all previous powers of attorney or authorizations of agent given in the applications identified in Table A attached hereto, and appoint

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the Correspondence Address for all applications identified in Table A to:

| Practitioners at Customer Number 52286 |

I am the:
| Applicant/Inventor.
| Assignee of record of the entire interest. (A statement under 37 CFR 3.73(b) is enclosed.)

Respectfully submitted,

ASTRAZENECA AB

Name: Christer Wahlström

Title: Director Patent Operations

ATTORNEY DOCKET NO.: AstraZeneca Ref.: 100848-1P US

#### **ASSIGNMENT**

Now, therefore, for good and valuable consideration, receipt and sufficiency of which is hereby acknowledged, I/we

Christopher BECKER, Bruce DEMBOFSKY, Robert JACOBS, James KANG, Cyrus OHNMACHT, James ROSAMOND, Ashokkumar Bhikkappa SHENVI, Thomas SIMPSON and James WOODS all of AstraZeneca Wilmington, P.O. Box 15437, Wilmington, DE 19850-5437, USA

hereafter referred to as ASSIGNOR (S),

Hereby sell(s), assign(s) and transfer(s) to ASSIGNEE AstraZeneca AB, a company created and existing under the laws of Sweden, having its Head Office at SE-151 85 Södertalje, Sweden, and the successors, assigns and legal representatives of the ASSIGNEE, the entire right, title and interest for the United States and its territorial possessions, and in all foreign countries, in and to the Inventions and any and all improvements thereon which are the subject of an application entitled:

#### **NOVEL LACTAMS AND USES THEREOF**

WITH ANTHOLIS MISCHOSER III	And	which	is	disclosed	in:
-----------------------------	-----	-------	----	-----------	-----

(a) 🗌	U.S. patent application executed on even date herewith;
(b) 🗌	U.S. patent application executed on;
(c) 🗌	U.S. application no;
(d) 🔯	International application no. PCT/SE2003/001534 filed on 2 October 2003

And in and to the above application and any legal equivalent thereof in a foreign country, including the right to claim priority, and in and to any division, continuation or continuation-in-part, renewal or substitute thereof, and in and to all resulting Letters Patents or any reissue or reexamination thereof, to have and to hold the same to the full end of the term or terms for which any and all of said Letters Patent may be granted;

ASSGNOR(S) authorize(s) and request(s) the issuing authority to issue any and all patents on said application or applications to said ASSIGNEE or its successors and assigns;

ASSIGNOR(S) hereby covenant(s) that ASSIGNOR(S) has/have the full power to make this assignment, and that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment; and

Without further payment or compensation by the ASSIGNEE or its successors and assigns, ASSIGNOR(S) further covenant(s) and agree(s) to communicate to said ASSIGNEE or its representatives, agents, its successors or assigns, any facts relating to said invention or inventions including evidence for purposes of interference or other administrative or legal proceedings whenever requested; to testify in any interference, legal or administrative proceedings, whenever requested; to execute and deliver, on request, all lawful papers required to make any of the foregoing provisions effective; and to do everything possible to aid said ASSIGNEE, its successors or assigns and nominees to secure, obtain and enforce proper patent protection for said Invention or inventions in this or any foreign country.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

IN WITNESS WHEREOF, I have hereunto set my hand and seal on the date below written.

Christopher BECKER	3/14/05
Signature of Assignor	Date of Assignor's Signature
WITNESSED BY:	
Elizabeth Ashton Signature of Witness Name of Witness Elizabeth Ashton (Type or print clearly)	Signature of Witness Name of Witness (Type or print clearly)
IN WITNESS WHEREOF, I have hereunto set my ha	and and seal on the date below written.
Bruce DEMBOFSKY Signature of Assignor	2/2//2005  Date of Assignor's Signature
WITNESSED BY:	
Eugabeth Ashton Signature of Witness Name of Witness Elizabeth Ashton (Type or print clearly)	Signature of Witness Name of Witness (Type or print clearly)  RANCES TOWKALDJIAN
IN WITNESS WHEREOF, I have hereunto set my ha	nd and seal on the date below written
Robert JACOBS Signature of Assignor	Date of Assignor's Signature
WITNESSED BY:	
Signature of Witness Name of Witness Elizabeth Ashton (Type or print clearly)	Signature of Witness Name of Witness (Type or print clearly)  FRANCES TOWN KAUDIAN
Additional signature pages attached: X Yes \( \sigma \) N	do

IN WITNESS WHEREOF, I have hereunto set my hand	and seal on the date below written.
James KANG Signature of Assignor	3-7-05  Date of Assignor's Signature
WITNESSED BY:	Signature of Witness Name of Witness FRAN Towtkaud I An (Type or print clearly)
IN WITNESS WHEREOF, I have hereunto set my hand	and seal on the date below written.
Cyrus Ohnmacht  Signature of Assignor	2/28/05  Date of Assignor's Signature
WITNESSED BY:  List of Witness Signature of Witness Name of Witness Elizabeth Ashton (Type or print clearly)	Signature of Witness Name of Witness FRAN TOWKALDIAM (Type or print clearly)
IN WITNESS WHEREOF, I have hereunto set my hand	and seal on the date below written.
James ROSAMOND Signature of Assignor	Date of Assignor's Signature
WITNESSED BY:	
Signature of Witness Name of Witness Elizabeth Ashton (Type or print clearly)	Signature of Witness Name of Witness (Type or print clearly) FRAN TOWKALDJIAN
Additional signature pages attached: X Yes No	

IN WITNESS WHEREOF, I have hereunto set my hand and seal on the date below written.

Ashokkumar Bhikkappa SHENVI Signature of Assignor	Date of Assignor's Signature
WITNESSED BY:  Likalith Canton  Signature of Witness Name of Witness Elizabeth Ashton (Type or print clearly)	Signature of Witness Name of Witness (Type or print clearly)
IN WITNESS WHEREOF, I have hereunto set my ha  //////// Thomas SIMPSON Signature of Assignor	nd and seal on the date below written.  2 2 5 05  Date of Assignor's Signature
WITNESSED BY:  Chalth Anton  Signature of Witness  Name of Witness Elizabeth Ashton  (Type or print clearly)	Signature of Witness Name of Witness (Type or print clearly)  FRANCES TOWKA LASTION
IN WITNESS WHEREOF, I have hereunto set my ha	nd and seal on the date below written.
James WOODS Signature of Assignor	2/25/05  Date of Assignor's Signature
WITNESSED BY:  Cligateth Ashton  Signature of Witness Name of Witness Elizabeth Ashton (Type or print clearly)	Signature of Witness Name of Witness (Type or print clearly)
Additional signature pages attached: Yes X	No